Pharmaceuticals Blogs 
This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 7.
The Op-Ed: Restoring Faith In Pharma Studies
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Harlan Krumholz is the Harold H. Hines Jr. Professor of Medicine and Professor of Investigative Medicine and of Public Health; director, Clinical Scholars Program; and director, Yale-New Haven Hospital Center for Outcomes Research and Evaluation. He is also a board member of the Patient-Centered Outcomes Research Institute.
A study in this week’s New England Journal of Medicine reveals that industry sponsorship of clinical trials negatively influences physicians’ perceptions of the study quality and their willingness to change practice based on the results. The findings should raise concerns throughout the pharmaceutic...
Source: Pharmalot - September 20, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Clinical Studies Harlan Krumholz industry-sponsored studies Pharmaceutical Advertising Pharmaceutical Marketing Physicians Source Type: blogs
The Op-Ed: A Suggestion to Restore Faith in Pharma StudiesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Our first invited guest blogger today is Harlan Krumholz, M.D., of Yale School of Medicine. Dr. Krumholz is the Harold H. Hines Jr. Professor of Medicine (cardiology) and Professor of Investigative Medicine and of Public Health (health policy); director, Clinical Scholars Program; and director, Yale-New Haven Hospital Center for Outcomes Research and Evaluation.)
A study in this week’s New England Journal of Medicine reveals that industry sponsorship of clinical trials negatively influences how physicians perceive the study quality and their willingness to change practice based on the results.The findings should raise ...
Source: Pharmalot - September 20, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Clinical Studies industry-sponsored studies Pharmaceutical Advertising Pharmaceutical Marketing Physicians Source Type: blogs
Pharmalot… Pharmalittle… Good MorningEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
It’s another glorious day on the Alternate Pharmalot Corporate Campus. We are (as I am sure you are) counting down the days until Ed’s return – he is totally AFK right now, and will only see what we’ve been up to upon his return. Today, there will be a few more op-eds and some news items for you. There’s a ton of stuff to get through today, as always, with conference calls, meetings, and that ever-present task that’s been needing your attention for some time, but take a little time to grab your favorite cup of stimulation and peruse some headlines:
Bayer CEO Decries Pressure to Lower Drug Pr...
Source: Pharmalot - September 20, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Affordable Care Act Autism Bayer Cancer Diabetes Fragile X Syndrome High Blood Pressure Multiple Sclerosis popcorn lung Suicide Source Type: blogs
Pharmalot…Pharmalittle…Good morningEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
It’s another glorious day on the Alternate Pharmalot Corporate Campus. We are (as I am sure you are) counting down the days until Ed’s return – he is totally AFK right now, and will only see what we’ve been up to upon his return. Today, there will be a few more op-eds and some news items for you.
There’s a ton of stuff to get through today, as always, with conference calls, meetings, and that ever-present task that’s been needing your attention for some time, but take a little time to grab your favorite cup of stimulation and peruse some headlines:
Bayer CEO Decries Pressure to Lower Drug Pr...
Source: Pharmalot - September 20, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Affordable Care Act Autism Bayer Cancer Diabetes Fragile X Syndrome High Blood Pressure Multiple Sclerosis popcorn lung Suicide Source Type: blogs
Er, no!Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Is Big Pharma getting too much flak from doctors?
By Frederik Joelving
NEW YORK | Wed Sep 19, 2012 10:06pm BST
(Reuters Health) - Big Pharma's image problem, fueled by numerous high-profile scandals, may have made doctors so skeptical of the industry that it's warping their judgment, a new survey suggests.
Researchers found that doctors shown summaries of hypothetical drug tests lost their confidence in the results when a pharmaceutical company had paid for the studies.
FREE GUIDES AND REPORTS FROM DIANOMI
ADVERTISEMENT
Doctors were less willing to prescribe the drug under study, and they even downgraded the very sc...
Source: PharmaGossip - September 19, 2012 Category: Pharma Commentators Authors: insider Source Type: blogs
The Op-Ed: Whistleblowers and the Real WorldEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Brian McCormick, a managing partner at the Sheller PC law firm in Philadelphia, discusses the personal challenges faced by pharma whistleblowers and the duty of their attorneys to spell out what may be in store for them.
I represent whistleblowers. I have worked closely with them throughout my whole career, even when I worked for a large defense firm and nobody else there knew what the False Claims Act was. Now I spend a great deal of my time interviewing clients and reviewing cases, many of them for pharmaceutical industry employees. As many of us in the qui tam field know, ensuring that a case actually exists and trying ...
Source: Pharmalot - September 19, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized False Claims Act Pharmaceutical Sales Reps Qui Tam Whistleblowers. FCA Source Type: blogs
The Op-Ed: Whistleblowers and the Real World – A Difficult but Necessary ConversationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Brian McCormick, a managing partner at Sheller P.C. in Philadelphia, discusses the personal challenges faced by pharma whistleblowers and the duty of their attorneys to spell out what may be in store for them.)
I represent whistleblowers. I have worked closely with them throughout my whole career, even when I worked for a large defense firm and nobody else there knew what the False Claims Act was. Now I spend a great deal of my time interviewing clients and reviewing cases, many of them for pharmaceutical industry employees. As many of us in the qui tam field know, ensuring that a case actually exists and trying to predic...
Source: Pharmalot - September 19, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized False Claims Act Pharmaceutical Sales Reps Qui Tam Whistleblowers. FCA Source Type: blogs
Would you like to guest blog from the ePharma Summit 2013?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
That’s right, we’re offering a few exclusive all-access complimentary passes to the ePharma Summit – March 4-6, 2013 in New York City and you could attend the conference – on us ($3,000+ value). We’re looking for experienced bloggers who are well-versed in viral Pharma marketing to begin blogging now and also at this year’s event. In return for your posts, you’ll be able to attend educational sessions and training seminars delivered by industry thought-leaders and Pharma professionals through in-depth case studies featuring the industry experts from leading pharmaceutical companies including sanofi-aventis, P...
Source: ePharma Summit - September 18, 2012 Category: Medical Marketing and PR Tags: Free ePharma Summit ePharam Source Type: blogs
Lawyers for Teen Boy Say J&J CEO Should Be Forced to TestifyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(This post is by Mia Burns, associate editor for Pharmalive.com)
Lawyers are saying J&J’s CEO Alex Gorsky ought to be forced to testify about claims that the company illegally marketed the antipsychotic Risperdal, which allegedly caused boys to grow breasts. This comes from a court filing for a teen-ager suing J&J. The jury will start hearing evidence about the boy’s claims on Sept. 24, and J&J lawyers say that Gorsky will be out of the country on that date. Gorsky became J&J’s CEO in February, and succeeded Bill Weldon.
The filing happened in a Philadelphia state court, and the 15-yea...
Source: Pharmalot - September 18, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Source Type: blogs
The Op-Ed: Mental Health Rights, Pharma, and the ElectionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(This is one of the series of op-eds we’ve solicited this week while Ed Silverman is on vacation. Jim Gottstein, from the Law Project on Psychiatric Rights, writes about developments in the mental health rights field, how pharma has contributed (positively or negatively), and how the upcoming election may influence that environment.)
First, in the interest of full disclosure, I work with the Law Project for Psychiatric Rights (PsychRights), whose mission is to mount a strategic litigation campaign against forced psychiatric drugging and electroshock around the country.
Second, before addressing developments in the m...
Source: Pharmalot - September 18, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Eli Lilly human rights Johnson & Johnson mental health rights Risperdal Zyprexa Source Type: blogs
FDA Approved Vaccine with Autism and SIDS Listed as Adverse Events, Vaccine Safety Website Removes InformationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CONCLUSION
The secret Simpsonwood meeting points to a direct causal relationship between vaccines and autism. This information prompted vaccine manufacturers to rapidly and very quietly manufacture a thimerosal-free vaccine with the FDAs full cooperation. I think parents need to keep that in mind.
Four years after a “thimerosal free” vaccine became available, a cryptic paragraph referencing autism and SIDS appeared in a vaccine product insert. Now that information is being scrubbed from government and vaccine safety websites. Shame on them!
And by the way, Mom and Dad, as of May 2, 2012, the Johns Hopkins Institute f...
Source: vactruth.com - September 18, 2012 Category: Health Medicine and Bioethics Commentators Authors: Jeffry John Aufderheide Tags: Jeffry John Aufderheide Top Stories adverse Reactions Autism Simpsonwood Conference Sudden Infant Death Syndrome (SIDS) Thimerosal Tripedia Source Type: blogs
Doing what it does bestEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Pharma Behaving Badly by TIME Healthland
Record-breaking multibillion-dollar settlements against big drug companies have become routine in the U.S. In recent years, pharmaceutical companies seem to have been playing a game of one-upmanship, each surpassing yet a new milestone of wrongdoing — fraudulently marketing their drugs or making misleading claims about their safety — and the threat of massive payouts appears to have offered little deterrent.
(MORE: Breaking Down GlaxoSmithKline’s Billion-Dollar Wrongdoing)
Even the largest of settlements rarely dent the profits associated with the drugs involved: for examp...
Source: PharmaGossip - September 18, 2012 Category: Pharma Commentators Authors: insider Source Type: blogs
Laptop Theft Puts 13,000 Clinical Trial Participants Personal Info at RiskEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(This item was produced by Mia Burns, assistant editor for Pharmalive.com)
A laptop theft from last week may have placed the personal information of about 13,000 current and previous clinical trial participants from about 50 different studies at risk, says Feinstein Institute for Medical Research. Terry Lynam with North Shore-LIJ Health System says that some of the clinical studies were drug trials, with the largest one being for rheumatoid arthritis.
“But there’s also various other studies involving other diseases such as Alzheimer’s, leukemia, and a host of other smaller studies,” Lynam says. “In the n...
Source: Pharmalot - September 17, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Clinical Trials data security data theft Source Type: blogs
Bayer Loses Nexavar Compulsory License BattleEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Mia Burns, assistant online editor for Pharmalive.com, produced this piece.)
Generic drug makers and disadvantaged patients are the winners here, because India’s Intellectual Property Appellate Board rejected a petition from Bayer on Friday that sought a stay on an order of Controller of Patents. What this now means is that the Hyderabad-based Natco Pharma Limited, a generic drug company, can act on its compulsory license for Bayer’s kidney and liver cancer drug Nexavar.
Natco received the first compulsory license ever to make a generic version of Bayer’s Nexavar back in March. In May, Bayer challenged ...
Source: Pharmalot - September 17, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Source Type: blogs
Pharma Sales Corruption in India. And How.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
I work in research. Early research, pulling-stuff-out-of-thin-air type early drug research. I'm about as far from the commercial end of the companies I've worked at as I can be, but it's the commercial end that pays my salary and keeps the labs running.
But that does not mean that everything that drug companies do to sell drugs is therefore justified. Far, far from it. Unfortunately, I have another entry today that will go into my category tag marked "The Dark Side". It's on drug sales tactics in India, which are explored by Frederik Joelving in this article at Reuters. It is not pretty:
The Abbott guide -- reps say the...
Source: In the Pipeline - September 17, 2012 Category: Chemists Tags: The Dark Side Source Type: blogs
The Op-Ed: Another Word on ‘Declining’ Drug Development ProductivityEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(As Ed Silverman is on vacation this week, we’re trying something new and getting some op-ed guest writers. Dan Hoffman, Ph.D., a partner in Clinical Trial Recovery Specialists, does his own analysis of a study that Sanford Bernstein analyst Tim Anderson said showed drug pipelines are still trending downward.)
Last week Sanford Bernstein’s Tim Anderson reviewed some data from KMR, a benchmarking and performance analytics group, and identified what he characterized as a “potentially disturbing” trend in pharma’s R&D productivity. Anderson’s commentary received a fair amount of attent...
Source: Pharmalot - September 17, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized BLAs Drug Development Drug Discovery Drug Pipelines NMEs Source Type: blogs
Pharmalot…Pharmalittle…Good morningEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Ed Silverman is on vacation this week, so it’s me again, Christiane Truelove, director of content for Med Ad News and Pharmalive.com, keeping an eye on the joint while he’s away. This week, however, we’re trying out something a little different – instead of trying to follow in Ed’s inimitable footsteps with the news and only the news, we’re having some specially chosen guest op-ed pieces. Each day, expect to see one or two articles from various viewpoints in the pharma industry. We aim to stoke some debate around here.
Now, here’s the usual roundup of news links to get your day started...
Source: Pharmalot - September 17, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Source Type: blogs
Bad Pharma: How drug companies mislead doctors and harm patientsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Here’s an unashamed plug for new book by Dr Ben Goldacre that’s out in a week or so.
‘Bad Science’ hilariously exposed the tricks that quacks and journalists use to distort science, becoming a 400,000 copy bestseller. Now Ben Goldacre puts the $600bn global pharmaceutical industry under the microscope. What he reveals is a fascinating, terrifying mess.
Doctors and patients need good scientific evidence to make informed decisions. But instead, companies run bad trials on their own drugs, which distort and exaggerate the benefits by design. When these trials produce unflattering results, the data is simply bu...
Source: seroxat secrets... - September 17, 2012 Category: Mental Illness Authors: admin Tags: Big Pharma Drug Marketing GlaxoSmithKline Study 329 Source Type: blogs
The LITFL Review 076Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This study suggest we maybe a bit premature in calling time of death in-hospital cardiac arrest patients.
The LITFL Review Shout Out of the Week
Emergency Medicine Education
Shout of the week goes to…..Emergency Medicine Education a relatively new blog by Kent Robinson (@drkentrobinson). Emergency Medicine Education is about is an open medical resource for those with a special interest in Emergency Medicine, and also targets those with a special interest in emergency medicine education.
See some of Kent’s recent post:
Crash-2 – “The Original” and CRASH-2 “The 2012 Update”
...
Source: Life in the Fast Lane - September 17, 2012 Category: Emergency Medicine Doctors Authors: Kane Guthrie Tags: Education eLearning Emergency Medicine Featured Health Intensive Care LITFL review Blogs critical care FOAM FOAMed LITFL R/V Source Type: blogs
Pharmac vs PharmaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Drug lobbyist attacks Pharmac
High risks for local development of medicines holding back excellent potential, says US industry advocate.
The way Pharmac operates is not only unfair on patients and drug companies that develop medicines, but it inhibits development in New Zealand, an advocate for US drug firms says.
The United States drugs industry is seeking major changes to the way Pharmac runs in ongoing Trans Pacific Partnership (TPP) talks.
Joseph Damond, a senior vice-president of the Washington-based Biotechnology Industry Organisation, was in Wellington last month to speak with politicians, including Trade Minist...
Source: PharmaGossip - September 17, 2012 Category: Pharma Commentators Authors: insider Source Type: blogs
Let the sun shine inEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Push to reveal fees paid to doctors
A PROPOSED revision to the pharmaceutical industry's code of conduct requires pharma companies to reveal total payments to doctors, but critics say individual payments should be disclosed.
Under the proposed changes being considered by the competition regulator, industry body Medicines Australia will publish aggregate details of fees paid by its members to doctors and consultants from mid-2014.
The fees include ''all consultancy services provided in relation to education meetings, preparation of promotional materials or product position papers, chairing and speaking at educational mee...
Source: PharmaGossip - September 16, 2012 Category: Pharma Commentators Authors: insider Source Type: blogs
Paul Thacker is now at HarvardEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A Challenge to Big Pharma
A recent article in the BMJ, by Lab Fellow Donald Light and Joel Lexchin, used FDA data to show that the pharmaceutical industry does not face the innovation crisis it has so widely publicized in order to make the public and legislators think that it needs more subsidies and government protection from free-market competition than it already has.
The article contends that major companies operate a "hidden business model" to exploit patents, as well as other market protections, and develop minor variations rather than clinically superior drugs for patients. Professor Light has published a separ...
Source: PharmaGossip - September 15, 2012 Category: Pharma Commentators Authors: insider Source Type: blogs
Lilly and social mediaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Editor’s note: Ed’s at a conference in D.C. right now; Deputy Ms. Pharmalot. Christiane Truelove, director of content for Med Ad News and Pharmalive.com, is watching things.) If you’re following any pharma companies on Twitter, it’s apparent that Eli Lilly is one of the most active. The company launched its blog, LillyPAD, two years ago; the blog, the Facebook page of the same name, and the Twitter feed from the blog focus on public policies about health care and pharmaceuticals. Additionally, Lilly has a Facebook page and Twitter account for the Campaign for Modern Medicine, which is a Lilly-owned...
Source: Pharmalot - September 14, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Blogs Lilly Social Media Source Type: blogs
Boehringer Ingelheim Releases SyrumEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
After much hesitation, many pharmaceutical companies are finally
beginning to use social media outlets to connect with their consumers. Boehringer Ingelheim recently launched the beta version for their Facebook game, "Syrum". The company hopes that it will help
educate, entertain, and gain more Facebook followers.
PMLive describes the game as akin to a cross between a card game like "Pokémon" and a Facebook game like "Farmville." The object is for players to solve a problem--e.g., a pandemic--via drug development, all the way from early discovery through clinical trials and launch. The game does not in...
Source: ePharma Summit - September 14, 2012 Category: Medical Marketing and PR Tags: 2012 ePharma syrum boehringer ingelheim Source Type: blogs
Kevin MD at #eDTC2012Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Our pal Kevin MD presented in Washington, DC this morning at the eDTC Revolution 2012 Conference. From looking at their website, looks like it was primarily a pharma crowd. I presented at an industry conference in San Francisco and let me tell you, it was a little bit of a tough crowd. Those pharma people really want and need access to physicians/providers.
Below are the tweets (via storify) from his talk via the hashtag to the conference #eDTC2012. I don't know if he is making his slides available, but you'll get a good idea of his talk from the tweets. Enjoy and have a great weekend everybody!
[View the st...
Source: Doctor Anonymous - September 14, 2012 Category: Internists and Doctors of Medicine Authors: Mike Sevilla, MD Source Type: blogs
Syrum, the first social game of pharmaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Yesterday, Boehringer launched a social game for pharma which is going to be a milestone in the history of pharma’s role in improving social media. Here is Syrum.
Boehringer Ingelheim last night unveiled its most ambitious attempt yet to harness the power of gaming at a consumer-style launch event held at the Science Museum in London.
Its long-awaited Facebook game Syrum challenges players to run their own pharmaceutical company and develop drugs to combat a range of deadly diseases.
Explaining the company’s reasons for developing the game Boehringer’s director of digital John Pugh told PMLiVE: “We built Sy...
Source: ScienceRoll - September 14, 2012 Category: Geneticists and Genetics Commentators Authors: Dr. Bertalan Meskó Tags: Game Pharma Web 2.0 Source Type: blogs
Up And Down The Ladder… Job ChangesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone?
And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Insmed hired Will Lewis as ceo and president. He succeeds Tim Whitten, who...
Source: Pharmalot - September 14, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Amgen AMRI Aratana Therapeutics Avista Capital Partners Circassia Daiichi Sankyo FDA Greenhill HD Smith Illumina Imprimis Insmed Janssen Kinex Pharmaceuticals Osmotica Pharmaceutical Raptor Pharmaceutical Re Source Type: blogs
Pharmalot… Pharmalittle… The Weekend NearsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
And so, another working week draws to a close. This is, as you know, our signal to daydream about weekend plans. Our agenda is modest and mostly involves catching up on sundry chores, a little reading and family time. And you? Have anything special planned? Perhaps this is a good time to go apple picking or visit the beach before the cold weather sets in. Or simply spend time with good friends. Whatever you do, enjoy, but be safe. Meanwhile, we would like to note that we will be leaving early today to give a speech and then will be on vacation next week. A colleague or two will run the show in our absence. We look forward ...
Source: Pharmalot - September 14, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Active Pharmaceutical Ingredients ALEC American Legislative Exchange Council Animal Health API Bayer BenGay Cornerstone Therapeutics Elspar FDA India JJ Johnson & Johnson Leukemia Lundbeck Malaysia Merck M Source Type: blogs
Former Biotech CEO Fights Exclusion By FedsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Yet another pharmaceutical industry executive is fighting a move by the US Department of Health & Human Services to exclude him from participating in federal healthcare programs. The latest to go to court is W. Scott Harkonen, who once headed InterMune and was sentenced earlier this year for wire fraud in connection with disseminating false and misleading statements about the results of a clinical trial of the Actimmune drug.
Last year, Harkonen was excluded for a five-year period as the result of a conviction in a September 2009 trial and was later sentenced last to three yeas’ probation, six months of home confine...
Source: Pharmalot - September 13, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Actimmune HHS OIG InterMune Purdue Pharma Scott Harkonen Source Type: blogs
A rose by any other name…Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
If it were a Hollywood Blockbuster, instead of a Pharmaceutical Blockbuster, it would be called:Return of the insulin-sensitizersOr…TZDs: the next generationOr…Insulin-sensitizers III, new blood.If it were a commercial product, it might be re-branded as a new-and-improved insulin-sensitizer:100% weight-gain free!Or…Now with less edema and death!But this is a (potential) pharma blockbuster, so instead it’s called a mitochondrial target of thiazolidinedione modulator. Say what?Read my report on the next potential game-changer in the medicine cabinet war against type 2 diabetes over a D’Mine. And don’t worry, inst...
Source: LifeAfterDx--The Guardian Chronicles - September 13, 2012 Category: Diabetes Authors: Wil Source Type: blogs
Pharma keeping a close eye on Latin AmericaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
When it comes to Latin America, the last thing that comes to
mind for many is, pharmaceuticals, but that may change very soon. Recently
opportunities for Pharma, as well as other industries are continuing to grow in
Latin American countries. Latin America is accessible and affordable, and
proving to be prominent for both sales and research. According to a
PharmPhorum.com summary, Latin America’s Pharma sector continues to grow
annually, their mortality rates are better, and due to the vast treatment for non-communicable
diseases, medical care is necessary.
Here
are a few reasons why Latin America should b...
Source: ePharma Summit - September 12, 2012 Category: Medical Marketing and PR Tags: 2012 ePharma Pharma Latin America Source Type: blogs
The Innovation Myth And A Challenge To PharmaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Last month, the BMJ published a controversial paper that maintained that the “widely touted innovation crisis in pharmaceuticals is a myth.” Rather, the authors contended that the “real innovation crisis” can be traced to R&D that produces “mostly minor variations” on existing drugs and incentives that reward drugmakers for such efforts. Meanwhile, they charged that many of the newer drugs caused an “epidemic” of serious side effects that added to healthcare costs.
The analysis actually continued a long-running debate over the pharma pipeline and its price tag, especiall...
Source: Pharmalot - September 12, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized ABPI Association Of British Pharmaceutical Industry Donald Light Drug Development Joel Lexchin Source Type: blogs
Harnessing The Promise Of Comparative Effectiveness ResearchEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The Federal Government has made an unprecedented effort to publicly finance research on the effectiveness of medical treatments. The Patient Protection and Affordable Care Act of 2010 established both the Patient-Centered Outcomes Research Institute and the Center for Medicare and Medicaid Innovation (CMMI) to promote this research and identify areas where new evidence on treatments [...]
Source: Health Affairs Blog - September 12, 2012 Category: Health Medicine and Bioethics Commentators Authors: Dana Goldman, Steven Schwartz, Darius Lakdawalla, Tomas Philipson, and Anupam Jena Tags: All Categories Comparative Effectiveness Consumers Pharma Policy Research Spending Technology Source Type: blogs
Australian Pharma Stall For Time On TranparencyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The bickering over a revised code of conduct for the pharmaceutical industry in Australia shows no sign of lessening. The latest installment involves disagreement over the maximum amount of fines that drugmakers would pay for violations, increased time to develop transparency rules, disclosing names of healthcare providers who receive industry payments and the virtues of disease awareness programs.
The months-long effort comes in the wake of the Physician Payments Sunshine Provision of the Affordable Care Act, which goes into effect next year and is designed to pull the curtain back on financial relationships between the p...
Source: Pharmalot - September 12, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Affordable Care Act Conflicts of Interest Medicines Australia Physician Payments Sunshine Sunshine Act Source Type: blogs
Pharmalot… Pharmalittle… Good MorningEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Good morning, everyone, and welcome to middle of the week. Another shiny day is unfolding on the Pharmalot corporate campus, where the official mascots are barking, the birds are chirping and yet another cup of stimulation is brewing. As always, we are preparing for a busy schedule filled with discussions, plenty of reading and some sleuthing. If you hear of anything interesting, drop us a line or a private Tweet. Meanwhile, here are some tidbits to help you along. Hope you accomplish much and have a wonderful day….
Sanofi To Outline Research Shakeup Soon (Reuters)
Fish Oil Pills Don’t Lower Heart Risks: Study...
Source: Pharmalot - September 12, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized AstraZeneca CanaRx Cancer Cancer Imaging China Controlled Substances Counterfeit Medicines CVS CVS Caremark DEA FDA Fish Oil Generics Heart Attacks Importation India Lancome Lundbeck Maine Merck Navi Source Type: blogs
Mirror Mirror on the Wall, Who's the Most Innovative of Them All? Pharma, Social Media Wise, That Is.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The pharmaceutical industry has consistently promoted itself as an "innovative industry" by which it means it discovers new, innovative drugs through research. No one ever claimed the drug industry was very innovative in marketing in general or in its use of social media. However, consultant and strategist Andrew Spong, just came close to doing that in a post titled "Innovation: the name of the game for Boehringer.""By dint of the sheer weight of evidence that has accrued over the past three years alone," says Spong, "Boehringer Ingelheim may reasonably be identified as the pharma company that sets the pace for the industr...
Source: Pharma Marketing Blog - September 11, 2012 Category: Pharma Commentators Tags: gamification Boehringer Ingelheim social media Syrum Bullshit Source Type: blogs
Careers, And Those Words "Stuck" and "Advance"Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A recent comment to another post prompts this entry. Regarding getting a chemistry PhD and getting a job, it reads:
. . .However, transitioning into corporate pharma was a big if not bigger challenge in some ways. It took a while to figure out how the system works and how to advance one's career and not get stuck in the lab.
Now this is a touchy subject, and it's two words in it that make it so: "advance" and "stuck". Pick one hundred chemists who start out in, say, industrial drug research at any given time (I know, bear with me - it's a thought experiment). Now observe them at the five year mark, the ten, and the twent...
Source: In the Pipeline - September 11, 2012 Category: Chemists Tags: Life in the Drug Labs Source Type: blogs
Sun Pharma Says Things Are Improving, But…Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Late last month, Sun Pharma happily declared that its Caraco unit was finally in compliance with good manufacturing practices after receiving notice from the FDA. This meant that two manufacturing and packaging facilities in Michigan were able to resume limited operations after various inspections and so-called 483 reports had been issued by the agency. Specifically, Caraco can now resume production of just two products – Carvedilol USP and Paramomycin USP
“Manufacturing of other products from these sites, including those pending approval with the USFDA, will be subject to similar rigorous approval procedure. ...
Source: Pharmalot - September 10, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Caraco Consent Decree FDA Nimodipine Pharmaceuticals International Sun Pharma Source Type: blogs
Healthcare may be late to social media, but how can they make up time?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Healthcare brands, both in the United States and Latin America still haven't received much guidance when it comes to digitally marketing their brands online. However, their consumers are online. Healthcare content, however, is readily available to the consumer. So what are a few tips Patricia Redsicker at Radian 6 offers for Pharma to use this content to better engage their customers?
1. Create value for your consumers. Many times in healthcare we see a one way conversation. But share valuable information your customers are looking for by giving them content that is relevant to them.
Redsicker point...
Source: ePharma Summit - September 10, 2012 Category: Medical Marketing and PR Tags: Pharma Content Marketing pharma marketing ePharma Summit Latin America Pharma digital marketing Source Type: blogs
Pharmalot… Pharmalittle… Good MorningEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Hello, everyone, and how was your weekend? Hopefully, the respite was relaxing. Now, though, that familiar routine of meetings and deadlines and whatever else has resumed in full force. We are no different, of course, and so we are fortifying our selves with that age-old cup of stimulation – Rain Forest Nut is our choice this morning – and invite you to join us. Meanwhile, please keep us in mind if you hear anything interesting. Hope your day goes well…
Lung Cancer Genomic Mapping Points Toward New Targets (New York Times)
Roche Ramps Up Alzheimer’s Drug Trial (Reuters)
AstraZeneca Halts Development...
Source: Pharmalot - September 10, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Abbott Laboratories Astellas AstraZeneca CMV Ephiredrine EpiPen Genome Gilead Sciences GlaxoSmithKline HIV Human Genome Ireland Lung Cancer Lupus Mylan Laboratories New Jersey New York NICE Pakistan Pa Source Type: blogs
European Respiratory Society Hides Multiple Financial Conflicts of Interest in Statement Opposing Electronic Cigarette UseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Last week, I revealed that the European Respiratory Society issued a statement that opposes the use of electronic cigarettes, but failed to disclose that the chair of the Society's tobacco control committee has received research funding from Pfizer, a pharmaceutical company that makes a product (Chantix) which is a competitor to electronic cigarettes in the smoking cessation market and thus stands to lose enormously if electronic cigarettes become more popular.Today, I reveal that the European Respiratory Society is also hiding from the public its own financial conflicts of interest with multiple pharmaceutical companies t...
Source: The Rest of the Story: Tobacco News Analysis and Commentary - September 10, 2012 Category: Health Medicine and Bioethics Commentators Source Type: blogs
The LITFL Review 075Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Welcome to the overwhelming 75th edition!
The LITFL Review is your regular and reliable source for the highest highlights, sneakiest sneak peaks and loudest shout-outs from the webbed world of emergency medicine and critical care. Each week the LITFL team casts the spotlight on the best and brightest from the blogosphere, the podcast video/audiosphere and the rest of the Web 2.0 social media jungle to find the most fantastic EM/CC FOAM (Free Open Access Meducation) around.
The Most Fair Dinkum Ripper Beaut of the Week
PHARM
This could go down the podcast of the year! Minh is brilliant as usual but this time he t...
Source: Life in the Fast Lane - September 10, 2012 Category: Emergency Medicine Doctors Authors: Kane Guthrie Tags: Education eLearning Emergency Medicine Featured Health Intensive Care Blogs critical care FOAM FOAMed LITFL R/V LITFL review Social Media Source Type: blogs
States' Rights: Regulation Via SettlementEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
"I believe in states' rights.... I believe we have distorted the balance of our government today by giving powers that were never intended to be given in the Constitution to that federal establishment."Ever since Ronald Reagan said he believed in "stats' rights" that has been the rallying cry of Republicans up to and including Romney-Ryan.For pharmaceutical companies, however, states' rights to enforce some federal laws via litigation is a problem. Take for example, the the $181 million settlement reached August 29 between 36 attorneys general and Jannsen Pharmaceuticals (a Johnson and Johnson company). According to a Forb...
Source: Pharma Marketing Blog - September 8, 2012 Category: Pharma Commentators Tags: off-label promotion Johnson and Johnson Legal/Regulatory Jannsen Source Type: blogs
Adherence - Do We Really Need an App for That? Benefits Do Not Outweigh the Risks.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Adherence, as defined in the Pharma Marketing Network Glossary, is "Percent of doses of a drug taken as prescribed for entire period of study (compliance + persistence)." In short, "sticking to the proper self-administration of treatment." Lots of patients -- even patients taking life-saving medication -- are not as "adherent" as they should be, which means that the treatment does not work as advertised and drug companies lose money. This has been discussed ad nauseum (see the links to articles listed here).There have been many attempts by the drug industry to improve medication adherence, but it has been a tough challenge...
Source: Pharma Marketing Blog - September 7, 2012 Category: Pharma Commentators Tags: Apps Mobile Adherence Jannsen Source Type: blogs
Production for ePharma Summit 2013 is well underwayEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Leading up to ePharma Summit 2013, conference director Sarah Gordon will give an inside look at what is going on behind the scenes. The event is currently in production, but you can sign up to receive the latest updates here.
Over the past month, I've had research calls and in-person meetings with more than 50 of your peers: some of which have attended ePharma, some have spoken at ePharma, and some didn't even know what ePharma is. Most people had positive feedback, some had not-so-positive feedback, but EVERYONE offered me insight into what matters most to the pharma marketing industry. One of my favorite parts...
Source: ePharma Summit - September 7, 2012 Category: Pharma Commentators Tags: ePharma Summit Source Type: blogs
European Respiratory Society Publicly Claims that Electronic Cigarettes Cause Cancer and Lies About Tobacco Industry Involvement in Creation of These ProductsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In a statement entitled "European Respiratory Society statement on E-cigarettes and emerging products," the European Respiratory Society tells the public that electronic cigarettes cause cancer.According to the statement: "The European Respiratory Society, ERS is opposed to the use of all tobacco and unapproved nicotine delivery products such as cigarettes, chewable tobacco, and emerging products that include electronic cigarettes (e-cigs), snus, dissolvable tobacco and waterpipes. In response to the successful increase in tobacco-free policies, the tobacco industry has developed these new products, allowing consumers to o...
Source: The Rest of the Story: Tobacco News Analysis and Commentary - September 7, 2012 Category: Health Medicine and Bioethics Commentators Source Type: blogs
KV Pharma Loses Lawsuit Against FDA Over MakenaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
REPEATING FROM LAST NIGHT: A federal judge has tossed a lawsuit filed two months ago by KV Pharmaceutical that claimed the FDA abdicated its responsibility to prevent some compounding pharmacies from offering lower-cost versions of its controversial Makena treatment for premature births. The decision, which could still be appealed, is the latest blow to the drugmaker and its fading hopes to build Makena into a blockbuster medication that will captivate investors.
In her ruling, US District Court Judge Amy Berman Jackson found that the FDA appropriately exercised its discretion in whether to pursue enforcement actions again...
Source: Pharmalot - September 7, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Active Pharmaceutical Ingredient API FDA KV Pharmaceutical Makena Orphan Drug Act Source Type: blogs
Up And Down The Ladder… Job ChangesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone?
And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we have a doubleheader. VaxInnate hired Christine Mayer (photo to the left) as vp of bu...
Source: Pharmalot - September 7, 2012 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Aragon Pharmaceuticals BioMarin Civitas Therapeutics Cubist Pharmaceutical Fedora Pharmaceuticals INC Research National Institutes of Health Navidea NIH Pulmatrix ReSearch Pharmaceutical Services Shire Pharmaceuticals Source Type: blogs
